Cannabis capital markets have faced significant challenges over the past few years. As investors who have been actively involved in the industry since 2019, we have had the privilege of experiencing every market cycle – from euphoric highs to sobering lows.
Despite these fluctuations, today’s market environment presents an unparalleled opportunity for discerning investors, thanks to unique deal structures, compelling valuations and the ability to identify and back exceptional management teams.
The marijuana industry’s struggles with access to capital have fundamentally reshaped the competitive landscape. Over the past two years, funding sources have dried up, leaving many companies to adapt or face extinction.
This environment has proved to be a litmus test for management teams. Companies that relied on continuous funding to mask operational inefficiencies are no longer able to do so.
This article was originally published on MJBizDaily, read the rest here.
Could 2025 Be a Bumper Year for Cannabis Capital Markets?
Cannabis capital markets have faced significant challenges over the past few years. As investors who have been actively involved in the industry since 2019, we have had the privilege of experiencing every market cycle – from euphoric highs to sobering lows.
Despite these fluctuations, today’s market environment presents an unparalleled opportunity for discerning investors, thanks to unique deal structures, compelling valuations and the ability to identify and back exceptional management teams.
The marijuana industry’s struggles with access to capital have fundamentally reshaped the competitive landscape. Over the past two years, funding sources have dried up, leaving many companies to adapt or face extinction.
This environment has proved to be a litmus test for management teams. Companies that relied on continuous funding to mask operational inefficiencies are no longer able to do so.
This article was originally published on MJBizDaily, read the rest here.
Australia’s Medical Cannabis Market Set to Outgrow Europe’s Biggest Players
Next PostCRS Research Says Cannabis Rescheduling Future ‘Unclear’ as Legal Challenges Emerge
MJBizDaily
Related Posts
Related Posts
US Spending Bill Takes Aim at Cannabis Rescheduling Project
As more details of the Trump administration’s fiscal plans for the year ahead come to light, so do more thinly...
Federal ‘Back Door’ Intoxicating Hemp Killing Bill Makes Passes First Hurdle
A Republican-led US House committee has advanced a controversial spending bill that would redefine hemp under federal law, placing sweeping...
Is the Golden Era of Thca Flower Coming to an End?
MediPharm On the Brink: Shareholder Revolt Reaches Boiling Point as Board Fight for Survival at Canandian Cannabis Giant
Uncertainty Kills: Inside the Cannabis Industry’s Battle with Trump’s Trade War
Cannabis Debt Crisis Intensifies as Lenders Circle Overleveraged Operators
CONNECT
Related Posts
Related Posts
US Spending Bill Takes Aim at Cannabis Rescheduling Project
As more details of the Trump administration’s fiscal plans for the year ahead come to light, so do more thinly...
Federal ‘Back Door’ Intoxicating Hemp Killing Bill Makes Passes First Hurdle
A Republican-led US House committee has advanced a controversial spending bill that would redefine hemp under federal law, placing sweeping...
Is the Golden Era of Thca Flower Coming to an End?
Steven Brown firmly believes THCA flower is federally legal hemp under the 2018 Farm Bill. But the CEO of Minnesota-based...
MediPharm On the Brink: Shareholder Revolt Reaches Boiling Point as Board Fight for Survival at Canandian Cannabis Giant
A bitter boardroom battle has erupted at MediPharm Labs, one of Canada’s leading pharmaceutical cannabis companies, as investor Apollo Capital...
Uncertainty Kills: Inside the Cannabis Industry’s Battle with Trump’s Trade War
The shock announcement this week that a federal trade court had ruled that key elements of President Trump’s flagship tariff...
Recent Posts
Related Posts
Countdown to Cannabis Europa London 2025: Celebrating Our Pioneering Sponsors
We are proud to be supported by some of the cannabis industry’s most forward-thinking and influential businesses. Their backing helps...
US Spending Bill Takes Aim at Cannabis Rescheduling Project
As more details of the Trump administration’s fiscal plans for the year ahead come to light, so do more thinly...
What Comes Next for UK Medical Cannabis?
Though large-scale reform does not currently appear forthcoming, there are small-scale, more targeted measures that could feasibly be taken by...
Much-Needed Or More Delays? UK Industry Responds to Upcoming ACMD Review of Cannabis-Based Medicines
The UK government has commissioned the Advisory Council on the Misuse of Drugs (ACMD) to carry out a formal review...
MediPharm On the Brink: Shareholder Revolt Reaches Boiling Point as Board Fight for Survival at Canandian Cannabis Giant
A bitter boardroom battle has erupted at MediPharm Labs, one of Canada’s leading pharmaceutical cannabis companies, as investor Apollo Capital...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags